Executive summary
U.S. Patent 5,904,922 claims methods of treating envenomation using purified avian (chicken) or other polyvalent antivenoms administered intravenously, with antibody composition requirements (greater than 50% venom-reactive immunoglobulin) and upstream manufacturing constraints (e.g., host immunized with whole venom that is not glutaraldehyde-pretreated; in related claims, affinity purification and a specific purification recovery profile). The claims are broad on route and therapeutic indication (IV treatment of envenomed mammals) but narrow on defined antivenom manufacturing attributes that can be used to distinguish competing antivenoms in freedom-to-operate (FTO) analysis. The competitive landscape risk is highest from antivenoms that share the same manufacturing logic (non-glutaraldehyde whole-venom immunization, high venom-reactive fraction, affinity purification) and lower from products that use alternative immunization/purification paradigms (fragmented IgG, pepsin digestion, glutaraldehyde-treated immunogens, or different IV formulation and purification metrics).
What does US patent 5,904,922 claim and what elements are legally decisive?
Claim set synopsis (independent and dependent themes)
The patent contains three clear claim “tracks”:
-
Chicken (avian) antivenom track (Claim 1)
- Provide purified chicken antivenom in aqueous therapeutic solution, IV injectable.
- Antivenom is obtained from a host immunized with whole venom that is not glutaraldehyde pretreated.
- Antivenom comprises yolk immunoglobulin with >50% venom-reactive.
- Treat by intravenously injecting into an envenomed mammalian subject.
-
Polyvalent antivenom track (Claims 6-11)
- Provide purified polyvalent antivenom in aqueous therapeutic amount, IV injectable.
- Must comprise immunoglobulin with >50% venom-reactive.
- Derived from a first polyvalent antivenom having two or more monovalent subpopulations.
- Purified so that >50% by weight of the monovalent subpopulations are recovered.
-
Affinity-purified neutralizing antivenom track (Claim 12)
- Provide affinity purified antivenom capable of neutralizing both C. atrox and C. durissus terrificus.
- Immunoglobulin >50% venom-reactive.
- Treat by IV injection.
Legally decisive limitations
For patent validity and infringement analysis, the critical “decision points” are not the list of venoms; they are the manufacturing and composition definitions:
-
Non-glutaraldehyde whole venom immunization (Claim 1)
This is often the strongest differentiator versus conventional antivenom platforms that use treated immunogens.
-
Yolk immunoglobulin with >50% venom-reactive (Claim 1)
“Venom-reactive fraction” is a measurable composition criterion, but infringement depends on how “venom-reactive” is defined/assayed in the specification and how the accused product is characterized.
-
Monovalent subpopulation recovery by weight >50% (Claim 6)
This ties the claim to a particular purification/partitioning scheme.
-
Affinity purification and dual-species neutralization (Claim 12)
This is specific enough to act as a “product feature trigger,” not just a treatment method.
Route (IV) and therapeutic use (“envenomed mammalian subject”) are standard in antivenom practice and can be harder to use as differentiators; they are typically not the main infringement differentiators.
What patents protect the same antivenom treatment methods in the US?
Featured snippets for patentability coverage
The closest protective zones around this kind of claim typically include:
-
IgY/yolk-derived or avian immunoglobulin antivenom manufacturing
Claims and continuation filings in this space often cover how to immunize the host (including whether venom immunogens are treated), how IgY is harvested, and how the venom-reactive fraction is enriched.
-
Affinity-purified antivenoms with defined neutralization spectra
These estates often overlap with Claim 12-style constructs (Crotalus atrox and C. durissus terrificus dual neutralization).
-
Polyvalent antivenoms built from monovalent subpopulations
Many families claim methods of generating polyvalent mixtures from monovalent components and controlling enrichment or recovery.
Why exact US overlap can’t be enumerated here
A reliable “which patents protect the same thing” comparison requires the patent’s full publication record and claim construction context (specifically the application number, family members, and specification details defining “venom-reactive,” purification steps, and host immunization controls). Your prompt provides only the claim text for 5,904,922 and not the bibliographic record needed to map the full claim scope to overlapping US families with precision.
Resulting actionable takeaway for freedom-to-operate
The highest infringement probability is from US-distributed antivenom products that are:
- IgY-derived (avian yolk) and made using whole venom immunogens not glutaraldehyde-pretreated, and
- sold/characterized as having >50% venom-reactive IgY/Ig by the patent’s assay logic, and
- administered IV in envenomation treatment.
The second-highest infringement probability comes from products that match the polyvalent purification structure (monovalent subpopulations recovered by weight and recombined into a purified polyvalent IV injectable) and those that are affinity purified to a dual neutralization profile.
When does US Patent 5,904,922 expire and what exclusivity timelines matter?
Patent term framework
For US patents issued in the early 1990s, the typical end of enforceability is driven by:
- standard utility patent term (20 years from earliest non-provisional effective filing date), plus potential adjustments, and
- any patent term adjustment due to USPTO processing delay.
Exclusivity concept limit
Method-of-treatment patents for antivenoms do not create FDA “regulatory exclusivity” the way a new chemical entity does. In antivenom markets, exclusivity is usually governed by the regulatory status of the biologic product (BLA) and whether exclusivity attaches to specific reference products or manufacturing changes, not by this method claim alone.
Critical practical point
For FTO in this space, enforceability usually ends when the last relevant family member expires or is invalidated. Without the patent’s filing history, PTA/TABA data, or family details, the exact expiration date cannot be stated accurately from the information provided.
Is the claims scope vulnerable for invalidity: lack of written description, indefiniteness, or obviousness?
1) Potential indefiniteness risks around “venom-reactive”
The claims require “greater than fifty percent is venom-reactive.” This can be vulnerable if:
- the patent does not define the assay conditions and reference standard to measure “venom-reactive” in a reproducible way, or
- “venom-reactive” could be interpreted as any binding vs functional neutralization.
Because the claim uses a numeric threshold, courts often scrutinize whether skilled artisans can determine the boundary between “venom-reactive” and non-reactive immunoglobulin with reasonable certainty.
2) Obviousness risk around “purified antivenoms” and IV treatment
IV antivenom use in envenomation is routine. The novelty has to be anchored in:
- the immunization processing control (“not glutaraldehyde pretreated”), and/or
- the Ig fraction enrichment (>50%), and/or
- the purification scheme (monovalent subpopulation recovery by weight; affinity purification).
If prior art discloses all those features in combination, the claim is vulnerable. If prior art discloses them separately, an obviousness argument often turns on whether there is a reason to combine and whether the claimed thresholds are critical.
3) Written description risks around extensive venom lists
Claims 2-5 and 8-11 enumerate broad venom taxa and specific venom species. Those lists can become a problem if:
- the specification does not provide enabling detail or working examples that support the full scope across the listed venoms, or
- the scope is so broad that some enumerated venoms are not actually supported.
However, when antivenom specificity is broad and based on immunization with whole venom, courts sometimes accept broad coverage if the manufacturing platform can be applied.
How do you design around the patent: what antivenom manufacturing choices avoid infringement?
Design-around levers mapped to claim elements
A. Neutralize the “not glutaraldehyde pretreated” limitation (Claim 1)
- Use immunogens prepared with glutaraldehyde pretreatment of whole venom (if commercially and immunologically acceptable).
- Use a different immunization modality not meeting the “host immunized with whole venom not glutaraldehyde pretreated” requirement.
This is likely the most direct design-around for Claim 1, because the manufacturing condition is explicit.
B. Avoid the >50% venom-reactive immunoglobulin threshold
- Adjust purification to reduce the venom-reactive fraction below the claimed threshold.
- Use different definitions of reactive fraction (if the assay logic in the patent can be circumvented).
This is technically harder because antivenom potency typically correlates with functional reactivity, and regulators typically require performance. Still, from a claim coverage standpoint, numeric thresholds can be a design-around target.
C. Avoid the polyvalent monovalent subpopulation purification/recovery criterion (Claim 6)
- Use a different architecture for polyvalent antivenom, e.g., mixing finalized monovalent lots without the “purified such that >50% by weight of monovalent subpopulations are recovered” step as claimed.
- Change purification math by using different partitioning and recovery methods.
D. Avoid affinity purification + dual neutralization pairing (Claim 12)
- If the accused product is not affinity purified, Claim 12 is harder to reach.
- If it does not neutralize both C. atrox and C. durissus terrificus to the level required by the claim’s definition, Claim 12 is also harder to reach.
What antivenoms are most likely to trigger infringement risk?
Highest risk profile
- Avian IgY yolk-derived antivenoms that are:
- produced from hosts immunized with non-glutaraldehyde-pretreated whole venom, and
- purified to yield >50% venom-reactive yolk immunoglobulin, and
- sold for IV treatment of envenomed mammals.
Medium risk profile
- Polyvalent antivenoms that are purified according to a monovalent subpopulation recovery schema consistent with Claim 6.
- Affinity-purified antivenoms that meet the dual neutralization constraint in Claim 12.
Lower risk profile
- Antivenoms that use standard mammalian (equine) IgG extraction or enzymatic digestion, where immunization or purification does not match the explicit manufacturing controls in the claims.
- Products using different routes (implied here as IV only) or where a non-IV formulation is the marketed use.
How strong is the patent estate for 5,904,922 specifically?
Strength drivers
- The claims have multiple concrete manufacturing constraints that can be used in infringement contentions.
- The “not glutaraldehyde pretreated” limitation is a clear, auditable upstream manufacturing feature.
- Numeric thresholds (>50%) can support enforcement if assay standards are well described.
Strength limiters
- Antivenom manufacturing often varies by supplier, and many products can be engineered to change immunogen treatment or purification metrics.
- Method claims face litigation complexity in proving the accused product’s manufacturing and composition characteristics.
- If the specification does not define “venom-reactive” and purification steps precisely, enforceability can weaken.
Net assessment
The patent’s enforceable strength is likely concentrated on products that are either (i) explicitly IgY-based with non-glutaraldehyde immunogens or (ii) explicitly produced using the claimed purification architecture. Broad IV treatment of envenomation alone is unlikely to map cleanly onto the claim without matching those manufacturing and composition limitations.
What is the Orange Book status of US 5,904,922?
Answer
The Orange Book lists approved small-molecule drugs and certain therapeutic biologics and drugs with regulatory exclusivity tied to FDA references. Antivenoms are typically regulated as biologics via BLA routes, and method patents are not necessarily listed in the Orange Book even when enforceable.
No status determination possible from provided data
Determining Orange Book status requires the specific drug product name(s) and the FDA reference product linked to this patent. That information is not present in the prompt.
How does 5,904,922 compare with other antivenom patent claim strategies (IgY, affinity purification, and polyvalent mixtures)?
Claim strategy taxonomy
-
Upstream immunization-process claims
5,904,922 is unusually specific about immunogen pretreatment and host immunization logic for chicken/avian sources.
-
Downstream composition and purification metrics
The patent pushes into measurable constraints: “greater than 50% venom-reactive” and “>50% by weight monovalent subpopulation recovery.”
-
Neutralization spectrum by target species
Claim 12 uses a dual-neutralization requirement (C. atrox and C. durissus terrificus). This resembles affinity-purified or target-focused product definitions found in enforcement-ready biotech patent strategies.
What this means commercially
- License leverage typically comes from manufacturing controls rather than clinical regimen claims.
- A supplier contesting infringement can focus on their immunogen processing and assay-based characterization.
Key Takeaways
- U.S. Patent 5,904,922 is a method-of-treatment patent for IV management of envenomation that is constrained by manufacturing-defined antivenom attributes, not just therapeutic intent.
- The most infringement-sensitive elements are:
- non-glutaraldehyde-pretreated whole venom immunization (Claim 1),
- >50% venom-reactive yolk immunoglobulin (Claim 1),
- >50% by weight recovery of monovalent subpopulations in polyvalent purification (Claim 6),
- affinity purification and dual neutralization of C. atrox + C. durissus terrificus (Claim 12).
- Design-around paths are most viable by changing:
- immunogen pretreatment,
- venom-reactive fraction metrics,
- polyvalent purification/recovery architecture,
- affinity purification and dual-target neutralization.
- Enforceability and overlap with competing US antivenom patent estates cannot be mapped precisely without the patent’s bibliographic record and the relevant product-to-patent link, which are not included in the provided input.
FAQs
1) Does US 5,904,922 cover antivenom administration even if the product is not derived from yolk immunoglobulin?
No. Claim 1 specifically recites “yolk immunoglobulin” for the chicken/avian antivenom track. The polyvalent track and affinity track use broader “immunoglobulin” language but each has additional manufacturing constraints.
2) Can a company avoid Claim 1 by using glutaraldehyde-pretreated venom for immunization?
Claim 1 requires “whole venom that is not glutaraldehyde pretreated.” If immunization uses glutaraldehyde-pretreated venom as a defining feature, that limitation is not met.
3) What does “greater than fifty percent is venom-reactive” practically require for infringement proof?
In practice it requires evidence that the accused antivenom’s immunoglobulin fraction meets the claimed threshold under the patent’s defined or implied assay criteria, and that the fraction is measured on the relevant immunoglobulin material.
4) Are the long venom species lists necessary for infringement?
They are used in dependent claims (e.g., Claims 2-5 and 8-11). Independent coverage depends on the manufacturing and treatment method features, not on meeting a specific venom list unless asserted via dependent claims.
5) Does the patent imply exclusivity against any IV antivenom?
No. The claims require specific antivenom manufacturing and composition limitations. IV administration and envenomation treatment alone do not capture all IV antivenoms.
References
- United States Patent 5,904,922 (claims provided in prompt).
